Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial
| Autor: | B. I . ERIKSSON, O. E. DAHL, N. ROSENCHER, A. A. KURTH, C. N. VAN DIJ K, S . P. FROSTICK, P. KALEBO, A. V. CHRISTIANSEN, S . HANTEL, R. HETTIARACHCHI, J . SCHNEE, H. R. BULLER, FOR THE RE-MODEL STUDY GROUP, BATTISTA BORGHI |
|---|---|
| Přispěvatelé: | B. I . ERIKSSON, O. E. DAHL, N. ROSENCHER, A. A. KURTH, C. N. VAN DIJ K, S . P. FROSTICK, P. KALEBO, A. V. CHRISTIANSEN, S . HANTEL, R. HETTIARACHCHI, J . SCHNEE, H. R. BULLER, FOR THE RE-MODEL STUDY GROUP [.., BATTISTA BORGHI, ], AMS - Amsterdam Movement Sciences, Orthopedic Surgery and Sports Medicine, ACS - Amsterdam Cardiovascular Sciences, Vascular Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
DABIGATRAN ETEXILATE Evening Pyridines medicine.medical_treatment Total knee replacement Hemorrhage PROPHYLAXIS Dabigatran law.invention Postoperative Complications DIRECT THROMBIN INHIBITOR Randomized controlled trial Double-Blind Method law medicine Humans Prodrugs Acute Coronary Syndrome Enoxaparin Arthroplasty Replacement Knee Aged Venous Thrombosis VENOUS THROMBOEMBOLISM TOTAL KNEE REPLACEMENT business.industry Incidence (epidemiology) Drug Administration Routes Anticoagulants Hematology Clinical Enzyme Tests Middle Aged Arthroplasty Surgery Treatment Outcome Direct thrombin inhibitor Anesthesia Benzimidazoles business Venous thromboembolism medicine.drug Follow-Up Studies |
| Zdroj: | Journal of thrombosis and haemostasis, 5(11), 2178-2185. Wiley-Blackwell |
| ISSN: | 1538-7933 |
| Popis: | Summary. Background: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery. Methods: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1–4 h after surgery, or subcutaneous enoxaparin 40 mg once-daily, starting the evening before surgery, for 6–10 days. Patients were followed up for 3 months. The primary efficacy outcome was a composite of total VTE (venographic or symptomatic) and mortality during treatment, and the primary safety outcome was the incidence of bleeding events. Results: The primary efficacy outcome occurred in 37.7% (193 of 512) of the enoxaparin group vs. 36.4% (183 of 503) of the dabigatran etexilate 220-mg group (absolute difference, −1.3%; 95% CI, −7.3 to 4.6) and 40.5% (213 of 526) of the 150-mg group (2.8%; 95% CI,−3.1 to 8.7). Both doses were non-inferior to enoxaparin on the basis of the prespecified non-inferiority criterion. The incidence of major bleeding did not differ significantly between the three groups (1.3% vs. 1.5% and 1.3% respectively). No significant differences in the incidences of liver enzyme elevation and acute coronary events were observed during treatment or follow-up. Conclusions: Dabigatran etexilate (220 mg or 150 mg) was at least as effective as enoxaparin and had a similar safety profile for prevention of VTE after total knee replacement surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text